SCHEMBL770832

SCHEMBL770832

O=C(CCNS(=O)(=O)Cc1ccccc1)N1CCCC2CCCCC21

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HSD11B1 P28845 4/20 0.47
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
HSD17B1 P14061 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
FKBP1A P62942 3/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771746 0.93 RAB9A (0.47) RAB9ANPC1SMN1; SMN2HSD11B1LMNA
SCHEMBL10138123 0.85 RAB9A (0.50) RAB9ANPC1SMN1; SMN2HSD11B1ALDH1A1
SCHEMBL770516 0.81 SMN1; SMN2 (0.49) RAB9ANPC1SMN1; SMN2LMNAMAPK1
SCHEMBL770259 0.80 HSD11B1 (0.59) RAB9ANPC1SMN1; SMN2HSD11B1DRD2
SCHEMBL771270 0.80 HSD11B1 (0.46) RAB9ANPC1SMN1; SMN2HSD11B1DRD2
SCHEMBL771367 0.79 PREP (0.55) RAB9ANPC1SMN1; SMN2HSD11B1MEN1
SCHEMBL770428 0.79 DPP4 (0.49) RAB9ANPC1SMN1; SMN2HSD11B1DRD4
SCHEMBL787074 0.78 RAB9A (0.48) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL770953 0.77 ALOX12 (0.48) RAB9ANPC1SMN1; SMN2HSD11B1MEN1
SCHEMBL771985 0.77 MEN1 (0.53) RAB9ANPC1SMN1; SMN2HSD11B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 RAB9A 2187/4885NPC1 97/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 RAB9A 2217/4885NPC1 104/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.